Alveolar Organoids in Lung Disease Modeling

Area of Science:

• * Organoid technology in regenerative medicine and disease modeling.
• * Stem cell biology and lung tissue engineering.

Background:

• * Lung organoids replicate in vivo lung structure and function.
• * Alveolar type 2 (AT2) cells possess stem cell properties for lung regeneration.
• * AT2 cells are crucial for producing surfactant and repairing lung epithelium.

Purpose of the Study:

• * To review the applications of lung organoids in pulmonary diseases.
• * To highlight the use of lung organoids in drug screening and personalized medicine.
• * To discuss stem cell-based therapeutics for lung repair and regeneration.

Main Methods:

• * Generation of lung organoids from alveolar type 2 cells and human-induced pluripotent stem cells (hiPSCs).
• * Characterization of organoid properties including morphology, gene expression, and cell interactions.
• * Utilization of organoids to model disease mechanisms (e.g., COVID-19, lung cancer, fibrosis).

Main Results:

• * Lung organoids recapitulate distal lung structures and AT2 cell functions.
• * hiPSC-derived alveolospheres serve as models for studying cell-cell interactions.
• * Organoids are effective in defining disease development mechanisms.
• * Lung organoids show promise in drug screening and personalized medicine.

Conclusions:

• * Lung organoids are versatile models for pulmonary disease research and drug development.
• * Stem cell-based approaches and understanding regeneration pathways are key for lung repair.
• * Further research into novel regulators of alveolar organoid generation is critical for advancing lung repair therapies.